Resources
237 Results (showing 71 - 80)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/20/2022 (updated 3/27/2024)
Researchers looked at survey responses from women of reproductive age across eight rural U.S. regions to determine the association between contraceptive use and SUD treatment, healthcare utilization, and substance use.
Posted 7/12/2022 (updated 3/27/2024)
Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/27/2022 (updated 3/27/2024)
The U.S. Department of Housing and Urban Development (HUD) announced a broad, new initiative to connect individuals and families to housing, health care, and supportive services. Total funding of $322 million is a supplement to HUD’s Continuum of Care (CoC) Program, with $43 million for incremental housing vouchers for at-risk households, and $54 million set aside for projects in rural areas.
Posted 6/27/2022 (updated 3/27/2024)
Naloxone leave behind programs are a popular public health intervention for combatting the opioid epidemic. These programs are designed for first responders to educate and equip high risk, nonmedical individuals to respond to opioid overdose scenarios. However, stigma and misconceptions regarding naloxone remain common among medical providers, including emergency medical services (EMS) members.
Posted 6/14/2022 (updated 3/27/2024)
In 2019, the National Institutes of Health (NIH) began supporting research on treatment for opioid use disorder in criminal justice settings. The Justice Community Opioid Innovation Network (JCOIN) studies the effectiveness of new medications and other interventions as part of the NIH HEAL Initiative – Helping to End Addiction Long-Term.
Posted 6/14/2022 (updated 3/27/2024)
On Wednesday, the U.S. Department of Health & Human Services announced nearly $15 million awarded to rural communities to continue addressing misuse of illegal and prescription drugs known as psychostimulants. These awards are part of the Rural Communities Opioid Response Program (RCORP), a multi-year initiative with $400 million invested since its start in 2018.
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 5/31/2022 (updated 3/27/2024)
With facts and figures about health status, behavioral risk factors, mortality, and access to care, the resource aims to inform rural health policy for four states – Arizona, California, New Mexico, and Texas – along the U.S. southern border. The chartbook is a collaboration between the FORHP-supported Rural & Minority Health Research Center and the National Rural Health Association.
Posted 5/11/2022 (updated 3/27/2024)
The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.